{"id":"ddp-synchronous-with-radiotherapy","safety":{"commonSideEffects":[{"rate":"30-90%","effect":"Nausea and vomiting"},{"rate":"20-80%","effect":"Neutropenia"},{"rate":"10-50%","effect":"Anemia"},{"rate":"5-30%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Kidney damage"}]},"_chembl":{"chemblId":"CHEMBL5095232","moleculeType":"Small molecule","molecularWeight":"382.89"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DDP, or cisplatin, is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which prevent DNA replication and transcription, ultimately leading to cell death. This mechanism is particularly effective in rapidly dividing cancer cells.","oneSentence":"DDP is a chemotherapy drug that works by interfering with DNA replication, making it difficult for cancer cells to divide and grow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:35.487Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Synchronous with radiotherapy for various cancers"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT06064097","phase":"PHASE2","title":"A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-25","conditions":"Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT05588219","phase":"PHASE2","title":"Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Yong Zhang,MD","startDate":"2022-12-01","conditions":"Uterine Cervical Neoplasms","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cisplatin"],"phase":"phase_2","status":"active","brandName":"DDP synchronous with radiotherapy","genericName":"DDP synchronous with radiotherapy","companyName":"Yong Zhang,MD","companyId":"yong-zhang-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DDP is a chemotherapy drug that works by interfering with DNA replication, making it difficult for cancer cells to divide and grow. Used for Synchronous with radiotherapy for various cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}